Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
43
Not yet recruiting, industry sponsors, Hematology and blood cancers, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting155
- Completed859
43 trials
Showing 1 to 25, recently updated first.
- A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated AnemiaPivotal-lookingNot yet recruiting
Kind Pharmaceuticals LLCIndustry
NCT07950215 · 240 participants (planned) · Start Feb 1, 2027 · Primary completion Dec 1, 2027
Drug: AND017 capsules; ESA · For: Anemia Due to Chronic Kidney Disease
- An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.Pivotal-lookingNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07951190 · 36 participants (planned) · Start Nov 16, 2026 · Primary completion Nov 25, 2032
Drug: Iptacopan · For: Complement Mediated Diseases e.g. PNH, IgAN
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07903506 · 750 participants (planned) · Start Feb 2027 · Primary completion Mar 2039
Drug: Anitocabtagene Autoleucel; Isatuximab and 6 more · For: Newly Diagnosed Multiple Myeloma
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07933432 · 300 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 14, 2029
Drug: QLS4131; Pomalidomide Capsules and 3 more · For: Relapsed or Refractory Multiple Myeloma
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.Pivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07914894 · 20 participants (planned) · Start Jan 26, 2027 · Primary completion May 17, 2028
Drug: FXS6837 Capsule · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hangzhou, China; Tianjin, China
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligiblePivotal-lookingNot yet recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07903272 · 1,000 participants (planned) · Start Dec 14, 2026 · Primary completion Jan 11, 2037
Drug: Ramantamig; Daratumumab and 4 more · For: Multiple Myeloma
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07910903 · 320 participants (planned) · Start Dec 2026 · Primary completion May 2030
Drug: CM336; CM313 and 3 more · For: Multiple Myeloma (MM)
Sites: Tianjin, China
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaPivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07896590 · 292 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: Orelabrutinib; ICP-248 · For: Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Sites: Bozhou, China; Hefei, China; Beijing, China · 46 sites in all
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07887672 · 600 participants (planned) · Start Jan 2027 · Primary completion Feb 2042
Drug: Anitocabtagene autoleucel; Daratumumab and 5 more · For: Newly Diagnosed Multiple Myeloma
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07885293 · 408 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: HS-10382; Imatinib and 3 more · For: Chronic Myeloid Leukemia
Sites: Wuhan, China
- A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaPivotal-lookingNot yet recruiting
Shanghai RAAS Blood Products Co., Ltd.Industry
NCT07876674 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2027
Drug: SR604 · For: Hemophilia A; Hemophilia A and B; Hemophilia B
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaPivotal-lookingNot yet recruiting
AmgenAmgen (AMGN)
NCT07223190 · 560 participants (planned) · Start Jun 30, 2028 · Primary completion Dec 30, 2031
Drug: Blinatumomab; Blinatumomab and 1 more · For: Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
- A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyPivotal-lookingNot yet recruiting
Bisirna Therapeutics (Suzhou) Co., Ltd.Industry
NCT07816237 · 70 participants (planned) · Start Oct 29, 2026 · Primary completion Sep 30, 2027
Drug: VSA012; Eculizumab (Soliris®) · For: Paroxysmal Nocturnal Hemoglobinuria, PNH
Sites: Beijing, China; Jilin City, China; Quanzhou, China · 14 sites in all
- A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07623187 · 540 participants (planned) · Start Nov 1, 2026 · Primary completion May 31, 2031
Drug: IPN60340 + azacitidine + venetoclax; Placebo + azacitidine + venetoclax · For: Acute Myeloid Leukaemia (AML); Acute Myeloid Leukaemia
- A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentPivotal-lookingNot yet recruiting
Swedish Orphan BiovitrumIndustry
NCT07786922 · 26 participants (planned) · Start Jul 31, 2026 · Primary completion Jun 30, 2028
Drug: Avatrombopag 20 mg Oral Tablet · For: Aplastic Anemia
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Pivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07784101 · 280 participants (planned) · Start Oct 2026 · Primary completion Oct 2032
Drug: ICP-248; Pirtobrutinib and 1 more · For: Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Pivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07753369 · 128 participants (planned) · Start Aug 2026 · Primary completion Dec 2030
Drug: TQB3909 Tablets; Bendamustine Injection and 2 more · For: Small Lymphocytic Lymppho; Relapsed/Refractory Chronic Lymphocytic Leukemia
Sites: Zhengzhou, China; Nanjing, China
- Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Pivotal-lookingNot yet recruiting
Dizal PharmaceuticalsIndustry
NCT07712588 · 880 participants (planned) · Start Sep 2026 · Primary completion Jan 2031
Drug: Birelentinib; Rituximab and 5 more · For: Diffuse Large B-Cell Lymphoma (DLBCL)
Sites: Chongqing, China; Harbin, China; Changsha, China · 5 sites in all
- A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Pivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07747090 · 90 participants (planned) · Start Dec 10, 2026 · Primary completion May 5, 2028
Drug: FXS6837 Capsule; Eculizumab infusion · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
- A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)Pivotal-lookingNot yet recruiting
Kyntra BioIndustry
NCT07722988 · 201 participants (planned) · Start Apr 2027 · Primary completion Sep 2030
Drug: Roxadustat; Placebo · For: Myelodysplastic Syndromes
- TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell LymphomaPivotal-lookingNot yet recruiting
Tarapeutics Science Inc.Industry
NCT07639879 · 180 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2029
Drug: TR115; Investigator's Choice · For: PTCL; NK T-Cell Lymphoma
Sites: Beijin, China
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaPivotal-lookingNot yet recruiting
CStone PharmaceuticalsIndustry
NCT05700448 · 150 participants (planned) · Start Jun 2027 · Primary completion Dec 2029
Drug: Sugemalimab; Placebo and 3 more · For: Extranodal NK/T-cell Lymphoma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07569757 · 260 participants (planned) · Start Jun 2026 · Primary completion Dec 2028
Drug: TQB2934 injection; Pomalidomide Capsule and 2 more · For: Multiple Myeloma
Sites: Bengbu, China; Hefei, China; Beijing, China · 49 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.